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Background: The literature describing the long-term use of lithium carbonate to reinstate reduced levels of white
blood cell counts in patients treated with clozapine is scarce. We describe a case of successful recommencement of
clozapine on a patient who developed risk level of neutropenia which was corrected by lithium carbonate. He was
followed up for a period of one year.
Case presentation: We report a 40-year-old Sri Lankan male who developed neutropenia and low white blood cell
counts following commencement of clozapine. We were successful in restarting clozapine after the addition of
lithium carbonate to increase the cell counts. Clozapine was increased to 700 mg a day with 500 mg of lithium
carbonate. The patient remains stable after one year with no further episodes of neutropenia.
Conclusion: Lithium carbonate can successfully be used to treat clozapine-induced neutropenia.
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It is estimated that approximately 30% of patients with
schizophrenia are resistant to typical and atypical anti-
psychotics and warrant treatment with clozapine. Cloza-
pine should be offered to patients with treatment resistant
schizophrenia (TRS) as it is the antipsychotic with most
robust evidence for improving psychopathology and the
quality of life [1]. However, clozapine carries a 0.9% risk of
causing agranulocytosis and 2.7% risk of neutropenia [2]
which could be fatal. Over 80% of such cases are seen
within the first 18 weeks of treatment. Some patients who
develop agranulocytosis may be genetically predisposed [3].
As a result, most clinicians are reluctant to initiate
clozapine on patients. Lithium carbonate has been known
to increase the white blood cell (WBC) counts in patients
with leucocytopenia due to oncological causes. This has
prompted clinicians to explore the possibility of using
lithium carbonate in clozapine-induced neutropenia.
Case presentation
Our patient is a 40-year-old Sri Lankan male who was
diagnosed with paranoid schizophrenia at the age of 22* Correspondence: dr.chathurie@gmail.com
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article, unless otherwise stated.years and was resistant to adequate trials of trifluopera-
zine, olanzapine and risperidone. Therefore, he was started
on clozapine. The patient had delusions of reference,
delusional perception and commanding hallucinations
which affected his day to day functioning to a great degree.
He lost his job as a result of ongoing psychopathology.
His baseline white cell counts were only marginally
higher than the levels recommended before initiating treat-
ment with clozapine. The effect of clozapine and lithium
carbonate on the leucocyte count of the patient is given in
Table 1.
In order to initiate clozapine, patients must have a
baseline WBC count of 4.0 ×103/μl and a neutrophil
count of 2.5 × 103/μl. Clozapine must be withheld if the
WBC count drops below the ‘red’ cut-off of 3.0 × 103/μl
or the neutrophil count falls below 1.5 × 103/μl.
In patients with benign ethnic neutropenia, the neu-
trophil count before commencement of clozapine is low
and persistently tends to be around the risk level. Our
patient had a low baseline WBC count of 6.02 × 103/μl
and a neutrophil count of 2.82 × 103/μl before initiation
of clozapine. The WBC and neutrophil counts decreased
to 4.9 × 103/μl and 2.0 × 103/μl respectively, at a clozapine
dose of 62.5 mg on day 9. In such patients lack of exercise,
being a non-smoker or simply having blood drawn at the
wrong time of day could result in clozapine treatmenttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Effect of clozapine and lithium carbonate on white blood cell and neutrophil counts
Day 0 1 7 9 10 11 13 14 16 20 27 34
Total dose of clozapine (mg) 12.5 50 62.5 0 12.5 50 75 150
Dose of lithium carbonate (mg) 250 500 500 500 500 500 500 500
White cell count (103/μl) 6.03 5.8 4.9 6.3 6.2 7.4 7.8 8.3
Neutrophil count (103/μl) 2.82 2.4 2.0 2.6 3.4 3.7 3.7 3.0
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for the patient [4]. Approximately 90% of WBC remains in
storage in the bone marrow. The total lifespan of a neutro-
phil is 11-14 days but they die within hours after entering
the circulation. Infection stimulates release and can triple
the WBC count in a matter of hours. Neutrophils can
either circulate freely in the bloodstream or marginate
after being released from the bone marrow.
Lithium increases the neutrophil count and total WBC
count both acutely and chronically [5]. This ‘side-effect’
of lithium has been used successfully to raise the WBC
during cancer chemotherapy and in patients treated with
carbamazepine. The mechanism by which lithium in-
creases neutrophil count is not completely understood
and the effect is poorly quantified. Neutrophilia does not
seem to be clearly dose related although a minimum
lithium serum level of 0.4 mmol/l may be required. A
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Figure 1 Effect of clozapine and lithium carbonate on white blood ce
dropped to 4.9 × 103/μl and 2.0 × 103/μl respectively at a clozapine dose o
of lithium carbonate.of 2.6 × 103/μls has been reported in patients treated
with lithium [6,7].
We restarted clozapine at a lithium level of 0.5 mmol/l
on day 14 in our patient when he had a neutrophil count
of 2.6 × 103/μl and a WBC count of 6.3 × 103/μl. He had
a mean neutrophil count of 5.16 × 103/μl and a mean
WBC count of 10.14 × 103/μl 6 months after initiation of
lithium. At 1 year he had a WBC count of 8.6 × 103/μl
and a neutrophil count of 5.2 × 103/μl. His mean lithium
level at the end of 6 months was 0.55mmol/l. and 0.43
mmol/l at the end of one year (Figure 1).
Conclusion
Our patient remains well and is currently employed.
However, there are potential risks that should be borne
in mind. Re-challenge with clozapine have faced with
successes [8] and failures. In a retrospective review of 53
cases of clozapine re-challenge in the United KingdomD16 D20 D27 D34 1 year
uration
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ll and neutrophil counts. The white blood cell and neutrophil counts
f 62.5mg/d. It increased to 6.3 × 103/μl and 2.6 ×103/μl after addition
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dyscrasia [9]. In 85% of the cases that developed a blood
dyscrasia on re-challenge, it occurred sooner, lasted
longer and was more severe than with the initial trial of
clozapine. Therefore, when deciding on re-challenge
with clozapine, clinicians must carefully weigh the risks
and benefits. Not only the possibility of another episode
of neutropenia, but toxic effects of lithium and other
side effects of clozapine need particular attention.
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